We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quotient Clinical Receives MHRA Supplementary Accreditation
News

Quotient Clinical Receives MHRA Supplementary Accreditation

Quotient Clinical Receives MHRA Supplementary Accreditation
News

Quotient Clinical Receives MHRA Supplementary Accreditation

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Quotient Clinical Receives MHRA Supplementary Accreditation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Quotient Clinical has announces that it has been awarded Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA).

This is one of the highest levels of accreditation in Europe and confirms that Quotient Clinical is qualified to perform the full range of Phase I trials, including First-in-Human (FIH) studies for low molecular weight chemical entities and biologics.

The MHRA voluntary accreditation scheme was introduced in April 2008 in line with recommendations from the MHRA clinical trial expert advisory group, to maximize subject safety, and provides formal guidance on the standards expected in a clinical unit conducting FIH studies.

Mark Egerton, Managing Director of Quotient Clinical comments, “Our MHRA Supplementary Accreditation provides volunteers and sponsors with additional reassurance of the high standards we apply in performing clinical studies. This award acknowledges our continued commitment to quality and safety and underpins our status as one of the leading clinical units in Europe.”
Advertisement